Multifunctional 5-aminolevulinic acid prodrugs activating 5 diverse cell-death pathways

The present invention provides drug conjugates comprising 5-aminolevulinic acid (ALA), an aldehyde and a carboxylic acid that may function as a histone deacetylase inhibitor (HDACI). These conjugates may serve as co-drugs which release a plurality of active species in vivo. The novel drug conjugates may be used, for the treatment or prevention of cancer in PDT-dependent and/or PDT-independent (nonPDT) treatments, as well as for cosmetic uses. In addition the present invention provides novel uses for both the novel and known compounds. According to some embodiments, the present invention provides drug conjugates (co-drugs) comprising (i) ALA, (ii) an aldehyde and (iii) a carboxylic acid that may function as a histone deacetylase inhibitor (HDACO for the treatment of anemia and/or for the induction of erythropoiesis.

Additional information can be provided upon request.

Project manager

Adi Elkeles
BD Manager

Project researchers

Ada Rephaeli
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Felsenstein Medical Res Center-Beilinson

Abraham Nudelman
Bar-Ilan University (BIU),

Zvi Malik
Bar-Ilan University (BIU),